Interleukin-1 (IL-1) is radioprotective and induces both circulating colony-stimulating factorls) (CSF) and IL-6 in mice. We evaluated the relationship among these three responses to IL-1 using anti-IL-1 receptor antibody 35F5. This This cycling is thought to depend on the presence of hematopoietic growth factors, such as CSFs and IL-6, and on direct interaction of IL-1 and IL-6 with early progenitor However, direct evidence that the above mechanisms are essential for radioprotection remains to be established.
Mice. CD2FI male mice were purchased from the Animal Genetics and Production Branch, National Cancer Institute, National Institutes of Health (Frederick, MD). Mice were quarantined on arrival and screened for evidence of disease before being released from quarantine. They were maintained in an AAALAC-accredited facility in plastic Micro-isolator cages on hardwood chip contact bedding, and given commercial rodent chow and acidified (HCl to a pH of 2.5) tap water ad libitum. Animal holding rooms were maintained at 70°F f 2OF with 50% 10% relative humidity, using in only moderate reduction of circulating CSF. Consequently, the level of circulating CSF after 35F5 treatment was still equivalent to levels of CSF that were induced by doses of IL-1 in the radioprotective range. Because treatment with 35F5 antibody resulted in the blocking of IL-1 -reduced radioprotection, the above results suggest that circulating CSF, by itself, may not be sufficient for radioprotection. This conclusion supports our previous results which showed that granulocyte-macrophage CSF (GM-CSF) and G-CSF were radioprotective only when administered with suboptimal doses of IL-1 . This is a US government work. There are no restrictions on its use.
at least 10 air changes per hour of 100% conditioned fresh air. The mice were on a 12-hour light-dark full-spectrum lighting cycle with no twilight. Mice were 8 to 12 weeks old when used. All cage cleaning, handling, and injections were performed in a laminar flow clean air unit.
Reagents. Human recombinant IL-la and anti-IL-1 receptor antibody (35F5), a rat anti-mouse monoclonal immunoglobulin G , [IgG,] were prepared at Hoffmann-La Roche (Nutley, NJ). Control rat IgG was purchased from Sigma Chemical Co (St Louis, MO).
The antibody and the recombinant IL-la were diluted in pyrogenfree saline on the day of injection. The antibody was given intraperitoneally (ip) according to the protocol previously developed at Hoffmann-La Roche (unpublished results, 1989), 6 hours before ip injection of IL-I. Mice were anesthetized with methapane and were exanguinated 2 to 3 hours after IL-I administration.
Mice were placed in Plexiglass containers and were given whole-body irradiation at 40 cGy/min by bilaterally positioned "Co elements. The number of surviving mice was recorded daily for 30 days.
Murine bone marrow stromal cell cultures
Irradiation.
Stromal cell culture. were established using a modification of the method described by Dexter et alZ0 for long-term marrow culutre. Briefly, bone marrow cells from one femur (approximtely 2 x IO' cells) of a 6-week-old C57B1/6J female mouse (Jackson Laboratory, Bar Harbor, ME) were cultured in a 25-cm3 tissue culture flask (Costar, Cambridge, MA) containing 5 mL minimum essential a medium (GIBCO, Grand Island, NY) supplemented with 25% horse serum, 1 x mol/L hydrocortisone 21-hemisuccinate (Sigma, St Louis, MO), and antibiotics. After 1 week of incubation at 33OC in a humidified atmosphere containing 5% CO,, 95% air, half of the culture medium was replaced. After an additional 2 weeks of culture, a sub-confluent monolayer of adherent stromal cells, as well as hematopoietic colonies, could be observed. At this time, the medium was changed to contain 10% fetal bovine serum (HyClone, Logan, UT), plus 10% horse serum and 5 x IO-' mol/L hydrocortisone, and the cultures were transferred to a 37OC incubator. Once confluent, cultures were trypsinized and passaged at 1-to 2-week intervals. During a 6-month selection period, several phenotypically distinct homogenous adherent stromal cell cultures were isolated. To determine the effect of 35F5 antibody on production of IL-1-stimulated cytokines, stromal culture cells were incubated for 72 hours with 130 pg/mL of IL-I in the presence or absence of 100 pg/mL 35F5 antibody or rat IgG. Supernatants were assayed as described.
IL-6 activity in the serum and stromal cell supernatants was determined by using the hybridoma growth factor assay described by Aarden et al." This method uses the IL-64ependent hybridoma, B9, in a conventional microproliferation assay. Briefly, individual samples were initially treated to several 10-fold dilutions in the assay medium (RPMI 1640, 10% fetal calf serum (FCS), 5 x mol/L 2-mercaptoethanol(2ME), and 50 pg/mL gentamycin). Samples were subjected to twofold serial dilutions in 96-well culture plates containing 0.1 mL of assay medium per well. We then added 2,000 B9 cells in 0.1 mL of assay medium to each well (final volume 0.2 mL). The cultures were incubated at 37OC in a humidified atmosphere of 5% CO,. After 72 hours, the cultures were pulsed with 0.5 pC 'H-thymidine/well for 18 hours, harvested onto glass fiber filters, and counted in a liquid scintillation counter. One hybridoma growth factor unit was defined as the reciprocal of the dilution that yielded 50% of the maximal 'H-thymidine incorporation.
Measurement of CSF activity in the serum and supernatant. Mice were bled 2 to 3 hrs after IL-1 injection, and serum was collected by centrifugation after clot formation. CSF activity was measured in pooled serum samples collected from 4 to 5 mice per treatment group per experiment. Supernatants were collected from the stromal cell cultures as described above.The bone marrow colony assay for CSF activity has been described in detail.' Briefly, C3H/HeJ bone marrow cells were enriched for mononuclear cells by density gradient centrifugation on lymphocyte separation medium (Litton Bionetics, Charleston, SC). The cells collected from the interface of the gradient were washed and resuspended in RPMI 1640 supplemented with antibiotics, glutamine, sodium bicarbonate, HEPES buffer, and 15% FCS. Three serial twofold dilutions of each serum sample (30%, 15%, and 7.5% vol/vol) or two fourfold dilutions of stromal cells supernatant sample (20% and 5% vol/vol) were prepared in this medium, and 0.2 mL of each dilution was added to each duplicate well in a 6-well tissue culture plate. A final cell suspension was prepared of 1 x lo5 cells/mL in complete medium supplemented with 0.35% Bacto-Agar (Difco, Detroit, MI) and maintained at 41OC. Immediately after resuspension of the cells in the agar-medium mixture, 1 mL of this medium was added to each well. Once solidified, the cultures were incubated at 37OC, 6% COz, for 6 to 7 days, at which time colonies (225 cells per colony) were counted under a dissecting microscope. CSF activity was expressed Measurement of IL-6 activity. as colony-forming units per milliliter, based on colony count within the linear part of the dilution curve. Statistical evaluation of the results was done using chi-square analysis.
Statistical analysis.

RESULTS
Effect of anti-IL-1 receptor antibody 35F5 on radiation sensitivity of mice. We have shown that pretreatment with IL-1 confers radioprotection on mice.22 Conversely, others have shown that radiation results in a subsequent increase in IL-1.23-26 To determine if endogenous IL-1 is important in protection from damage by ionizing radiation, mice were administered the 35F5 antibody, control rat Ig, or saline before midlethal irradiation ( Table 1) . The results show clearly that pretreatment with the 35F5 antibody reduces the survival of mice significantly.
The effect of 35F5 antibody on radioprotection induced by IL-1. The 35F5 antibody has been shown to block the effect of IL-1 only on selected cell populations: fibroblasts and T-lymphoid cells, but not myeloid cells and B lymphocyte^.'^,'^ Therefore, we determined whether treatment with 35F5 could reduce the radioprotective effect of IL-1. Experimental mice were administered the 35F5 antibody, while control mice were treated with either rat Ig at equivalent concentrations or saline 6 hours before injection of 0.3 pg of IL-1, and exposed to lethal irradiation 20 hours later. The results demonstrate that even the 30-pg dose of the antibody almost completely blocked the radioprotective action of IL-1 (Table  2) . Dose-dependence of the radioprotective effect and CSFinducing effects of IL-I. We have previously shown that IL-1 induces the release of CSF into circulation.' The increase in circulating CSF and the corresponding increase in radioprotection is dependent on the dose of IL-1 ( Table 3) . The results show that at IL-1 doses above 0.1 pg, the titers of CSF approach plateau values (Tables 3 and 4) . However, For radioprotection increases more gradually, with 0.1 pg of IL-1 conferring 40%; 0.3 pg, 75%; and 0.5 pg, 83% protection. A dose of 0.05 pg of IL-1 conferred only limited radioprotection, but a significant increase in circulating CSF.
The eflect of 35F5 antibody on levels of CSF in circulation. To determine if induction of CSF with IL-1 was also blocked by 35F5, we used IL-1 in concentrations of 0.1 pg and 0.5 pg, doses just above and below those used in the radioprotection experiments (0.3 pg). Table 4 (Table 4) . Thus, we observed a more complete abrogation in IL-6 than in CSF.
The eflect of 35F5 antibody on production of CSF and IL-6 by stromal cells. IL-1 has been shown to induce production of CSF and IL-6 in bone marrow stromal cells.
The type of IL-1 receptor on these cells has not been determined. Therefore, the effect of 35F5 antibody on IL-1-induced production of CSF and IL-6 by stromal cells was examined in vitro. IL-1-induced production of IL-6 and CSF was found to be reduced in the presence of 35F5 antibody ( Table 5) . Rat IgG, alone or in the presence of IL-1, did not effect CSF or IL-6 production (results not shown). These results show that 35F5 anti-IL-1 receptor antibody blocks stromal cell responses to IL-1, indicating that these cells express receptors similar to those on EL-4 cells.
DISCUSSION
Anti-IL-1 receptor antibody (35F5) administered to mice before irradiation with 825 cGy rendered them more susceptible to the lethal effects of radiation. This result provides the first direct evidence that endogenously produced IL-1 plays an important role in protection from radiation injury. It has been observed previously that radiation induces production of IL-1.23-26 In view of the present results, the presence of endogenously produced IL-1 after irradiation may represent a natural defense mechanism of the host against damage from ionizing radiation. Furthermore, our previous finding that treatment with pharmacologic doses of IL-1 (10 pg/ mouse) after irradiation protects mice from death,27 suggests that insufficient amounts of IL-1 may be produced endogenously because an additional exogenous supply of IL-1 is required for a greater degree of protection. Figure 1 summarizes the effects of 35F5 on radioprotection ( Table 2 ) and on serum CSF and IL-6 production ( Table  4) . Anti-IL-1 receptor antibody 35F5 administered to mice before injection of recombinant IL-1 reduced the radioprotective effects of IL-1 from 81% survival to 8% survival. Increasing doses of antibody (from 30 pg to 150 pg) had no additional effect. However, the same dose of antibody (30 pg) that blocked the radioprotective effect of IL-1 resulted in a comparatively small (between 16% and 50%) reduction in the titers of circulating CSF. Thus, despite the remaining high titers of circulating CSF, 92% of IL-1-treated mice given antibody succumbed to radiation-induced lethality. Increasing the dose of antibody to 150 pg reduced the CSF production, which was induced by 0.1 pg of IL-1, by 95%. Therefore, it appears that higher doses of 35F5 antibody can block the appearance of CSF in the circulation.
The 30-pg dose of 35F5 antibody not only blocked IL-1-induced radioprotection, but also greatly reduced the level of IL-6 in circulation. These results suggest that cells with For personal use only. on September 24, 2017. by guest www.bloodjournal.org From negligible contribution of macrophages to the levels of IL-6 and CSF in circulation. Another explanation may be based on the need for a second factor, in addition to IL-1, to stimulate the macrophages. The fact that IL-6 has been shown to synergize with a variety of CSFs to enhance colony growth of specific progenitor populations"~'' may underlie the apparent preferential inhibition of 35F5 on IL-6 versus CSF activity. The whole serum, which presumably contained a mixture of CSFs, may have shown reduced colony-forming activity, not due to decreased production of CSF, but rather due to elimination of synergizing IL-6. Alternatively, a specific species of CSF may have been affected by treatment. Clearly, the use of CSF-type specific antibodies will be necessary to determine whether a lower dose of 35F5 antibody blocks only the release of selected hematopoietic growth factors.
Our results show that an increase of CSF in circulation was initially a function of the dose of IL-I, but reached a plateau at doses exceeding 0.1 pg of IL-1 (Tables 3 and 4) : with differences not observed at dose increases ranging from 0.3 to 0.5 pg. In contrast, radioprotection was dosedependent in a more gradual fashion, with 0.05-pg doses conferring protection to 25% of mice, 0.1 pg protecting 40%, and 0.3 to 0.5 pg protecting 75% to 83% of mice. Comparison of the results leads to the conclusion that the mere presence of high titers of CSF in circulation is not sufficient for radioprotection (Tables 2 through 4 ). This conclusion is also supported by the observation that IL-1-induced radioprotection is strain-~pecific,'~ whereas IL-1-induced CSF is observed in all mouse strains.
The It is notable that, in vitro, stromal cells produce CSF in substantial quantities within 72 hours, even in the absence of IL-1 (Table 5) . However, addition of IL-1 results in much higher C S F titers, which are decreased to background levels by 35F5. This leads to the conclusion that 35F5 blocks IL-1-induced CSF production. These results support the hypothesis that IL-1 stimulates bone marrow stromal cells to produce other cytokines, such as IL-6 and CSF, which synergize with IL-1 to stimulate bone marrow progenitor cells and thus counteract the damaging effects of lethal irradiation.
